What an osteochondral lesion of the talus actually means

The talus is the dome-shaped bone sitting at the top of your ankle, bearing the full weight of your body with every step. When the cartilage on its surface is damaged — along with a portion of the bone beneath it — the result is an osteochondral lesion of the talus, or OLT.

Most people reach a clinic months or even years after what felt like a routine sprain. That delay is understandable: up to 50% of ankle sprains and over 70% of ankle fractures are associated with cartilage damage, yet the injury rarely appears on a standard X-ray. The characteristic symptoms — a deep aching pain inside the ankle, a catching or locking sensation, and swelling that returns reliably after activity — are easily mistaken for a ligament injury that is simply taking a long time to settle.

The reason your ankle has not recovered on its own comes down to biology. Articular cartilage has no blood supply of its own, which means it cannot mount the repair response that bone or muscle can. In young, active adults aged 20–40 — the group most commonly affected — a lesion that forms after trauma tends to persist or enlarge rather than resolve without targeted treatment.

MRI is the key diagnostic step because it confirms both the size and depth of the lesion. That measurement is not merely administrative: lesion size directly shapes which treatment options are likely to succeed, and it is the starting point for every clinical decision that follows.

How ChondroFiller works as an injectable collagen scaffold

Collagen is the structural protein your cartilage is built from, and it is the foundation of ChondroFiller Liquid (marketed as Liquid Cartilage™) — a CE-marked Class III medical device composed of acellular, injectable Type I collagen. No cells are added to the product itself; that distinction is central to how it works.

When the liquid is placed into the cartilage defect under ultrasound guidance, it gels within minutes, conforming to the shape of the lesion and forming a stable three-dimensional scaffold. This is not a filler in the cosmetic sense, and it is not a lubricant like hyaluronic acid, which the joint clears within weeks without contributing to structural repair.

What happens next is the process formally called acellular matrix-induced chondrogenesis — in plain terms, the scaffold draws the patient's own progenitor cells into the defect. Stem cells migrating from the surrounding synovium and subchondral bone enter the collagen matrix, receive signals from its structure, and begin differentiating into chondrocyte-like cells capable of producing cartilage matrix. Preclinical research into injectable collagen systems has demonstrated complete healing with a hyaline cartilage phenotype and biomechanical properties similar to adjacent native tissue, alongside down-regulation of inflammatory signalling pathways.

Over subsequent months, the collagen scaffold biodegrades gradually as the new tissue matures. The goal is hyaline-like cartilage repair — structurally superior to the fibrocartilage that bone marrow stimulation typically produces. This also separates ChondroFiller from surgical cell-implantation procedures such as autologous chondrocyte implantation (ACI), which require laboratory-grown cells to be grafted in a second operation. ChondroFiller supports the body's own repair processes; the cellular work is done entirely by the patient.

What the outpatient injection appointment involves

The appointment itself is conducted in an outpatient clinic room, not an operating theatre. There is no general anaesthetic, no surgical incision, and no theatre admission.

Before the injection, the treating consultant reviews existing imaging — principally MRI, to confirm the lesion's size, location, and depth. At MSK Doctors, this review may incorporate onMRI™ AI-assisted analysis to support precise lesion characterisation. Suitability is established at this assessment stage, so the procedure appointment itself is straightforward.

On the day of treatment, local anaesthetic is applied around the ankle. An ultrasound probe then guides the needle to the exact site of the cartilage defect within the talar dome, allowing the collagen solution to be deposited accurately into the lesion. Unlike arthroscopic procedures, which require the joint to be emptied of fluid to create a working space, this image-guided injectable approach is delivered into the joint as it normally exists — an important reason why no operating-theatre environment is required.

Most patients leave the clinic the same day. Without surgical incisions, wound care, or theatre recovery, the rehabilitation profile differs substantially from post-surgical pathways. Activity guidance — typically including a short period of protected weight-bearing — is provided at the time of treatment.

The outpatient pathway is accessible directly: no GP referral is needed, and appointments can be booked through mskdoctors.com.

How injectable treatment compares to ankle cartilage surgery

Surgery remains the most established route for complex ankle cartilage lesions, and for refractory or large-cyst cases it often is the right choice. The comparison here uses the main surgical options as reference points — not as the default against which an injectable treatment simply falls short.

Bone marrow stimulation (microfracture) is arthroscopic, the most common surgical first line, and produces fibrocartilage rather than hyaline cartilage — a repair tissue that is structurally weaker than the native surface. Lesion size is the dominant predictor of outcome: data from Chuckpaiwong et al. (2008) found no treatment failures for lesions below 15 mm in average diameter, but only a 3% success rate at 15 mm and above; a separate series of 168 lesions by Choi et al. (2009) placed the practical MRI cut-off at 150 mm². Reoperation rates reach up to 41% over time.

ACI and MACI achieve hyaline-like tissue repair, but require two operative stages — biopsy first, then implantation following laboratory cell expansion — with complication rates of up to 17%.

The ChondroFiller injectable pathway avoids theatre admission, arthroscopic access, and debridement of the joint bed. The collagen scaffold is placed under ultrasound guidance into the fluid-filled joint, preserving surrounding structures rather than displacing them. Comparative data from the Clinical Evaluation Report (Version 09, April 2025) indicate approximately 0% complications and 3–8% reoperation rates, with hyaline-like repair reported at defects up to 6 cm².

Longer-term durability of scaffold-based OLT repair is supported by evidence from adjacent techniques. A 10-year follow-up study of 85 patients using a hyaluronic acid membrane combined with bone marrow aspirate concentrate — a different product from ChondroFiller, but one that shares the core biological principle of an implanted scaffold recruiting the patient's own progenitor cells — found AOFAS scores rising from 59.1 to 82.3 (p<0.0005) and NRS pain falling from 7.1 to 3.9. It is that shared scaffold-and-cell-migration mechanism, rather than the specific product, that makes this finding relevant: it suggests biological scaffold repair in the ankle can sustain meaningful benefit across a decade.

Surgery retains a clear role where lesions require fixation, subchondral cysts need addressing, or prior procedures have failed. The injectable route is most relevant where a clinic-based, structure-preserving pathway is appropriate and lesion characteristics fall within its validated range.

The evidence behind ChondroFiller in ankle cartilage repair

ChondroFiller's regulatory status — CE-marked Class III, the most stringent device category under European medical device regulation — obliges the manufacturer to maintain an updated Clinical Evaluation Report. Version 09 of that report, published April 2025, is the regulatory anchor for the outcomes summarised here.

Real-world use now exceeds 20,000 implantations across more than a decade of clinical practice. MRI-based MOCART scores — a validated measure of cartilage fill, tissue integration, and surface regularity — range from 70 to 87 across published studies, indicating sustained structural repair quality over a 10-year follow-up horizon.

The most frequently cited outcome scores — approximately 30-point IKDC improvement in the knee, with comparable gains in hip series — derive predominantly from knee and hip data. As of April 2025, ankle-specific AOFAS and NRS figures are not separately reported within the CER summary; that gap is worth stating plainly rather than glossing over. The product and scaffold mechanism are CE-cleared across multiple joints including the ankle, and adjacent scaffold research in the talus — covered in the previous section — adds meaningful biological support to the ankle indication. What is not yet available is a dedicated ankle outcome dataset drawn from ChondroFiller specifically.

There is no standalone randomised controlled trial for ultrasound-guided ChondroFiller injection in the ankle. The evidence is mechanistically well-grounded, underpinned by regulatory-grade safety data and a substantial real-world implantation record — but a pivotal ankle RCT remains an open item. For patients weighing this pathway, that distinction is worth holding alongside the broader data: the safety profile is well-characterised, the rationale for ankle use is scientifically coherent, and ankle-specific outcome evidence continues to develop.

Who is most likely to benefit and next steps

The clearest candidates for an injectable scaffold assessment are active adults — typically in the 20–40 age range — with an MRI-confirmed focal OLT, ongoing symptoms despite a genuine trial of physiotherapy and activity modification, and a lesion that falls within the treatable size range. When ankle pain remains disproportionate to conservative care and limits daily function, the ChondroFiller pathway merits serious consideration.

Not every presentation will suit it. Lesions with extensive subchondral cyst involvement, established ankle osteoarthritis, or a history of prior failed scaffold surgery may require a surgical evaluation first; a consultant review clarifies which route is appropriate for the specific lesion and its history.

MSK Doctors holds consultant-led appointments in Sleaford, Lincolnshire and Grantham; where onMRI™ AI-assisted MRI analysis adds diagnostic clarity, it can inform same-visit decision-making. London-based patients can access the same injectable collagen scaffold pathway through the London Cartilage Clinic.

Consultant appointments at MSK Doctors can be booked directly at mskdoctors.com. The practical takeaway from the evidence reviewed here is deliberately modest: there is a biologically coherent, well-monitored injectable option for focal ankle cartilage lesions, with a safety profile and surgical-comparator data that justify its place in a serious clinical assessment — but individual suitability depends on lesion characteristics that only a face-to-face review can confirm.

1. [1] The influence of cell and platelet number on clinical outcomes provided by a one-step scaffold transplantation with bone marrow concentrate for OLTs. (2025). https://doi.org/10.1016/j.fas.2025.01.014 https://doi.org/10.1016/j.fas.2025.01.014
2. [2] Managing osteochondral lesions of the talus with anterior ankle arthroscopy. (2025). https://doi.org/10.24129/j.reacae.32284.fs2504010 https://doi.org/10.24129/j.reacae.32284.fs2504010